Sanofi

CAC 40Health careSANFR0000120578

A. is a French multinational pharmaceutical and healthcare company headquartered in Paris.

Filings

431 filings

All Inside information267 Share buyback113 Voting rights and capital36 Earnings release9 Half-year financial report2 Universal registration document2 Threshold crossing1 Annual financial report1

22/12/2025
Sanofi: Information concerning the total number of voting rights and shares - November 2025
Voting rights and capitalFR
22/12/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
19/12/2025
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
Inside informationFR
17/12/2025
Press release: Availability of the Q4 2025 Aide memoire
Inside informationFR
17/12/2025
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
Inside informationFR
15/12/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
15/12/2025
Communiqué de presse : Sanofi fait le point sur le tolébrutinib dans la sclérose en plaques primaire progressive
Inside informationFrench
15/12/2025
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
Inside information
15/12/2025
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire du tolébrutinib dans la sclérose en plaques secondaire progressive non-récurrente
Inside informationFrench
15/12/2025
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
Inside information
11/12/2025
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases
Inside informationFR
08/12/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
04/12/2025
Press Release: Sanofi completes acquisition of Vicebio
Inside informationFR
01/12/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
25/11/2025
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Inside informationFR
24/11/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
17/11/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
14/11/2025
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Inside informationFR
13/11/2025
Sanofi: Information concerning the total number of voting rights and shares – October 2025
Voting rights and capitalFR
10/11/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
07/11/2025
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Inside informationFR
03/11/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
31/10/2025
Sanofi: Disclosure of trading in own shares - Revised
Share buybackFR
28/10/2025
Press release: Sanofi successfully prices USD 3 billion of bond issue
Inside informationFR
27/10/2025
Sanofi : Déclaration des transactions sur actions propres
Share buybackFrench
24/10/2025
Press release: Q3: continued sales and earnings progress
Earnings releaseFR
22/10/2025
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Inside informationFR
20/10/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
20/10/2025
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Inside informationFR
20/10/2025
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
Inside informationFR
20/10/2025
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Inside informationFR
17/10/2025
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Inside information
17/10/2025
Communiqué de presse : Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire
Inside informationFrench
17/10/2025
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Inside information
17/10/2025
Communiqué de presse : Sanofi fournit une mise à jour de l’examen réglementaire du Rezurock dans l’UE pour le traitement de la maladie chronique du greffon contre l’hôte
Inside informationFrench
14/10/2025
Sanofi: Information concerning the total number of voting rights and shares - September 2025
Voting rights and capitalFR
13/10/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
08/10/2025
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
Inside informationFR
06/10/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
29/09/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
24/09/2025
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Inside information
24/09/2025
Communiqué de presse : Sanofi engage 625 millions de dollars supplémentaires dans Sanofi Ventures, afin d’accélérer ses investissements dans les biotechnologies et l’innovation en matière de santé numérique
Inside informationFrench
24/09/2025
Press release: Availability of the Q3 2025 Aide mémoire
Inside information
24/09/2025
Communiqué de presse : Mise en ligne du document "Q3 2025 Aide mémoire"
Inside informationFrench
23/09/2025
Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Inside informationFR
22/09/2025
Sanofi: Disclosure of trading in own shares
Share buybackFR
22/09/2025
Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
Inside information

About

ISIN: FR0000120578
Ticker: SAN
LEI: 549300E9PC51EN656011
Sector: Health care
Founded: 2004
Employees: 106,566
Country of registration: FR
Last filing: 04/08/2026, 07:00

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive